Citizens reiterates Amentum stock rating on Sellafield contract win

Citizens maintained its Market Outperform rating and $40 price target on Amentum after discussing the Sellafield award, a contract valued at up to $2.8 billion over an initial nine years; the stock was cited at $21.87. Amentum’s fiscal Q3 2026 adjusted EPS was $0.67 versus a $0.40 forecast, on approximately $3.5 billion of revenue, and the company raised its full-year outlook. Analyst views remain mixed: UBS kept Neutral with a $24 target, while BTIG retained Buy after lowering its target to $30 from $35.

Analysis

The Sellafield award is better read as continuity of incumbent work than as wholly incremental growth: Amentum may protect revenue and utilization, but the headline ceiling is not committed revenue, and the multi-year term makes near-term earnings contribution dependent on mobilization, task orders, and execution. The key value driver is therefore conversion into funded work at acceptable margins—not the contract’s maximum value. A long-duration services award also carries labor-cost and delivery risk; if escalation clauses do not keep pace with wages and other costs, backlog can grow while economics disappoint.

The recent earnings strength is encouraging, but the cited contribution from stronger segment profitability and lower interest expense means investors should test whether operating improvement persists independently of financing effects. The long-term-growth framing and low PEG are not sufficient valuation evidence without normalized earnings, cash conversion, and balance-sheet context. Analyst target dispersion should be treated as uncertainty about those fundamentals, not as a price catalyst.

Over the next 1–3 months, watch for confirmation of the award’s final scope, funded task orders, backlog conversion, and whether guidance is supported by organic growth and free cash flow. Over 6–18 months, execution and margin retention matter more than headline backlog. A contrarian risk is that the market may be treating a renewal-like award as a step-change in growth; conversely, if margins and cash conversion improve while revenue remains steady, expectations may still be too cautious. Amentum’s peers, including Jacobs, KBR, Leidos, and Parsons, could face competitive pressure for adjacent government-services work, but the article does not establish a direct displacement.

Key Decisions for Investors

• Avoid buying solely on the contract ceiling or the $40 analyst target. Treat AMTM as a conditional, measured long only if subsequent disclosures confirm funded work and sustained operating cash generation.
• For an existing position, hold but keep sizing disciplined; reassess if guidance or reported margins weaken, or if backlog rises without corresponding revenue and cash conversion.
• Set a 1–3 month watch item for final award status, task-order funding, organic growth, and free-cash-flow conversion. Failure to demonstrate conversion would falsify the bullish backlog interpretation.
• Do not initiate a peer short on this announcement alone. Revisit relative positioning only if Amentum’s execution evidence shows a durable advantage or if competitors disclose lost awards in overlapping scopes.